Overview on Rodent Models of Alzheimer's Disease
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
In Alzheimer's disease (AD), characteristic lesions develop in brain regions that subserve cognitive functions, ultimately leading to dementia. There are now several lesioned or transgenic small‐animal models of the disease that model select aspects of cognitive deficits and/or recapitulate many, but not all, of the characteristic pathologic lesions observed in AD. This overview describes the most common approaches used to model AD in rodents, highlights their utility, and discusses some of their deficiencies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198 · cited 1×
“Loss of cholinergic nerve cells within the basal forebrain is typical of AD (Bartus et al., 1982; Coyle et al., 1983; Giacobini, 1990; Francis et al., 1999).”
BackgroundEnhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611 · cited 2×
“…tangles have also been reported in the brain of JNPL3 mice after intracerebral injection of Aβ fibrils, or in double APP/tau tg mice (TAPP mice), suggesting that Aβ or amyloid can induce formation of neurofibrillary tangles under certain conditions (Götz et al., 2001; Lewis et al., 2001).”
BackgroundSoluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease
Lue, L.-F., Kuo, Y.-M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J. H., Rydel, R. E., & Rogers, J. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65184-x · Cited by 1,530 · cited 1×
“However, recent reports strongly support a disruptive action of a soluble species of Aβ on behavior (Lue et al., 1999; McLean et al., 1999; Walsh and Selkoe, 2004), suggesting that acute brain Aβ infusion may be sufficient to induce learning and memory impairments.”
Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526 · cited 2×
“Importantly, increased numbers of neurofibrillary tangles have also been reported in the brain of JNPL3 mice after intracerebral injection of Aβ fibrils, or in double APP/tau tg mice (TAPP mice), suggesting that Aβ or amyloid can induce formation of neurofibrillary tangles under certain conditions (Götz et al., 2001;…”
BackgroundTwo amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507
Borchelt, D. R., Thinakaran, G., Eckman, C. B., Lee, M. K., Davenport, F., Ratovitsky, T., Prada, C.-M., Kim, G., Seekins, S., Yager, D., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80230-5 · Cited by 1,478
Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447 · cited 1×
“…pathology in one or more tg mouse models of AD (Schenk et al., 1999; Lim et al., 2000; Bard et al., 2000; Janus et al., 2000; Morgan et al., 2000; Cherny et al., 2001; DeMattos et al., 2001; Dovey et al., 2001; Lim et al., 2001; Refolo et al., 2001; Sigurdsson et al., 2001; Dodart et al.,…”
BackgroundAβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431
Holcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386
Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Murphy, M. P., Baker, M., Yu, X., et al. (2000) · Nature Genetics · doi:10.1038/78078 · Cited by 1,371 · cited 2×
“Lewis et al. (2001) crossed APPoverexpressing Tg2576 mice with JNPL3 tg mice (Lewis et al., 2000), which express a mutant form of human tau (P301L).”
BackgroundAmyloid, the presenilins and Alzheimer’s disease
Hardy, J. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)01030-2 · Cited by 1,370 · cited 4×
“Indeed, several genetic mutations associated with earlyonset AD have been identified in the APP, presenilin (PS) 1, and presenilin 2 genes, which are located on chromosomes 21, 14, and 1, respectively (Hardy, 1997).”
BackgroundInfluentialDeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · cited 2×
“APP-processing enzyme inhibitors, antiinflammatory or cholesterol-lowering drugs, metal chelators, and active and passive immunization against Aβ have provided exciting and promising results, as all of these treatments either prevent or reduce amyloid pathology in one or more tg mouse models of AD (Schenk et al., 1999…”
BackgroundSelf-citationBillings, L. M., Oddo, S., Green, K. N., McGaugh, J. L., & LaFerla, F. M. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.040 · Cited by 1,294
Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-wood, K., Lee, M., Seubert, P., Davis, A., et al. (1997) · Nature Medicine · doi:10.1038/nm0197-67 · Cited by 1,271 · cited 1×
“By contrast, tg mice expressing either a wt or mutated PS gene fail to develop significant AD-like pathology (Borchelt et al., 1996; Duff et al., 1996; Citron et al., 1997; Oyama et al., 1998; Chui et al., 1999).”
BackgroundDeciphering the Molecular Basis of Memory Failure in Alzheimer's Disease
Walsh, D. M., & Selkoe, D. J. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.010 · Cited by 1,207 · cited 1×
“However, recent reports strongly support a disruptive action of a soluble species of Aβ on behavior (Lue et al., 1999; McLean et al., 1999; Walsh and Selkoe, 2004), suggesting that acute brain Aβ infusion may be sufficient to induce learning and memory impairments.”
Plaque-independent disruption of neural circuits in Alzheimer’s disease mouse models
Hsia, A. Y., Masliah, E., McConlogue, L., Yu, G.-Q., Tatsuno, G., Hu, K., Kholodenko, D., Malenka, R. C., Nicoll, R. A., & Mucke, L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.3228 · Cited by 1,123 · cited 1×
“Several other tg mice have been created that express mutant human APP transgenes alone (Hsiao et al., 1996; Sturchler-Pierrat et al., 1997; Hsia et al., 1999; Moechars et al., 1999; Chishti et al., 2001), or in combination with mutant human PS genes (Borchelt et al., 1997; Holcomb et al., 1998,…”
BackgroundBorchelt, D. R., Ratovitski, T., van Lare, J., Lee, M. K., Gonzales, V., Jenkins, N. A., Copeland, N. G., Price, D. L., & Sisodia, S. S. (1997) · Neuron · doi:10.1016/s0896-6273(00)80974-5 · Cited by 1,023
In vitro characterization of conditions for amyloid-β peptide oligomerization and fibrillogenesis
Stine, W. B., Dahlgren, K. N., Krafft, G. A., & LaDu, M. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210207200 · Cited by 1,015 · cited 2×
“Since the in vitro conditions for Aβ oligomerization and fibrillogenesis are not completely understood (Stine et al., 2003), it is unclear which types of Aβ preparation are optimal for inducing learning and memory impairments.”
BackgroundChishti, M. A., Yang, D.-S., Janus, C., Phinney, A. L., Horne, P., Pearson, J., Strome, R., Zuker, N., Loukides, J., French, J., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100710200 · Cited by 955 · cited 4×
“…of transgene expression in the brain has in fact been shown to differ depending on the choice of promoter (Andrä et al., 1996), and the extent of neuropathology can vary due to the different gene constructs employed (Sturchler-Pierrat et al., 1997; Moechars et al., 1999; Chishti et al., 2001).”
BackgroundInfluentialHoltzman, D. M., Bales, K. R., Tenkova, T., Fagan, A. M., Parsadanian, M., Sartorius, L. J., Mackey, B., Olney, J., McKeel, D., Wozniak, D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050004797 · Cited by 937
Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
Dodart, J.-C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., DeLong, C. A., Wu, S., Wu, X., Holtzman, D. M., et al. (2002) · Nature Neuroscience · doi:10.1038/nn842 · Cited by 858 · cited 1×
“…more tg mouse models of AD (Schenk et al., 1999; Lim et al., 2000; Bard et al., 2000; Janus et al., 2000; Morgan et al., 2000; Cherny et al., 2001; DeMattos et al., 2001; Dovey et al., 2001; Lim et al., 2001; Refolo et al., 2001; Sigurdsson et al., 2001; Dodart et al., 2002b; Jantzen et al., 2002).”
Self-citationLack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E. M., Little, S. P., Cummins, D. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-263 · Cited by 830
The Pathogenesis of Senile Plaques
DICKSON, D. W. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199704000-00001 · Cited by 753
A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease
Chen, G., Chen, K. S., Knox, J., Inglis, J., Bernard, A., Martin, S. J., Justice, A., McConlogue, L., Games, D., Freedman, S. B., et al. (2000) · Nature · doi:10.1038/35050103 · Cited by 740
Moechars, D., Dewachter, I., Lorent, K., Reversé, D., Baekelandt, V., Naidu, A., Tesseur, I., Spittaels, K., Haute, C. V. D., Checler, F., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6483 · Cited by 668
Irizarry, M. C., Soriano, F., McNamara, M., Page, K. J., Schenk, D., Games, D., & Hyman, B. T. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-18-07053.1997 · Cited by 497 · cited 1×
“…within the entorhinal cortex, the CA1 hippocampal subfield, and the cingulate cortex of PDAPP mice (ranging in age from 8 to 18 months), have failed to reveal evidence of neuronal loss compared to agematched non-tg mice, in marked contrast to what is observed in AD brain (Irizarry et al., 1997).”
ResultChui, D.-H., Tanahashi, H., Ozawa, K., Ikeda, S., Checler, F., Ueda, O., Suzuki, H., Araki, W., Inoue, H., Shirotani, K., et al. (1999) · Nature Medicine · doi:10.1038/8438 · Cited by 364 · cited 1×
“By contrast, tg mice expressing either a wt or mutated PS gene fail to develop significant AD-like pathology (Borchelt et al., 1996; Duff et al., 1996; Citron et al., 1997; Oyama et al., 1998; Chui et al., 1999).”
BackgroundHoltzman, D. M., Bales, K. R., Wu, S., Bhat, P., Parsadanian, M., Fagan, A. M., Chang, L. K., Sun, Y., & Paul, S. M. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6179 · Cited by 349 · cited 1×
“…extended these findings and further demonstrated that human apoE expression in PDAPP mice lacking murine apoE initially delays Aβ and amyloid deposition with apoE2, and to a lesser extent apoE3, showing a more prolonged effect (Holtzman et al., 1999; Holtzman et al., 2000; Fagan et al., 2002).”
BackgroundIntroduction and expression of the 400 kilobase precursor amyloid protein gene in transgenic mice
Lamb, B. T., Sisodia, S. S., Lawler, A. M., Slunt, H. H., Kitt, C. A., Kearns, W. G., Pearson, P. L., Price, D. L., & Gearhart, J. D. (1993) · Nature Genetics · doi:10.1038/ng0993-22 · Cited by 311
Yamada, K., Tanaka, T., Han, D., Senzaki, K., Kameyama, T., & Nabeshima, T. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00408.x · Cited by 238 · cited 1×
“…alternation: deficits after a 8-day treatment Water maze: deficits after a 2-week treatment Passive avoidance: retention deficits after an 18-day treatment Yamada et al. (1999) 25-35 Single dose: 15nmol i.c.v. 16 days before testing Rat Spontaneous alternation: deficits Social recognition:…”
MethodGeula, C. (1998) · Neurology · doi:10.1212/wnl.51.1_suppl_1.s18 · Cited by 184
Carlson, G. A., Borchelt, D. R., Dake, A., Turner, S., Danielson, V., Coffin, J. D., Eckman, C., Meiners, J., Nilsen, S. P., Younkin, S. G., et al. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.11.1951 · Cited by 158
Cited by
Mitochondrial dynamics-fusion, fission, movement, and mitophagy-in neurodegenerative diseases
Chen, H., & Chan, D. C. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp326 · Cited by 1,458
Neurovascular function in Alzheimer's disease patients and experimental models
Nicolakakis, N., & Hamel, E. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.43 · Cited by 156
Post-mortem analysis of neuroinflammatory changes in human Alzheimer’s disease
Gomez-Nicola, D., & Boche, D. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0126-1 · Cited by 147
“In AD, the amyloid plaque burden increases with age in both mouse models [44] and human patients [45], indicating the rather ineffective phagocytic potential of microglia.”
BackgroundCross Currents in Protein Misfolding Disorders: Interactions and Therapy
Morales, R., Green, K., & Soto, C. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789541998 · Cited by 72
“The stable characteristic of A β accumulation in transgenic mice [74–76] and the constant incubation periods for prions [13] should make these studies easy to follow.”
Patten, A. R., Yau, S. Y., Fontaine, C. J., Meconi, A., Wortman, R. C., & Christie, B. R. (2015) · Brain Plasticity · doi:10.3233/bpl-150016 · Cited by 64
“Studies of adult hippocampal neurogenesis in a variety of available transgenic rodent models of AD (reviewed by [188]) have generated contradictory results [156, 189].”
Background
Metadata
- Authors
- Dodart, J., & May, P.
- Venue
- Current Protocols in Neuroscience
- Publisher
- Wiley
- Published
- 2005-10
- Volume
- 33
- Issue
- 1
- Pages
- Unit 9.22-Unit 9.22
- ISSN
- 1934-8576 (ISSN-L)
- 1934-8584
- OpenAlex
- W1500301258
- Cited by
- 32
- References
- 33
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.